Aplicações Tecnológicas do Polimorfismo Farmacêutico
Palavras-chave:
Sólidos farmacêuticos. Polimorfismo. Engenharia de cristais moleculares.
Resumo
Sólidos farmacêuticos podem apresentar diferentes arranjos arquitetônicos de suas estruturas cristalinas. Este fenômeno é conhecido como polimorfi smo e, no caso dos fármacos, pode impactar sobre propriedades farmacotécnicas e farmacocinéticas. Em última análise, o emprego de uma forma polimórfi ca inadequada no estágio de formulação ou qualquer transformação entre fases durante o processamento e estocagem pode resultar em inefi cácia farmacêutica ou até mesmo em toxicidade. Isto destaca que o conhecimento das possíveis formas polimórfi cas que um fármaco pode apresentar é essencial para assegurar o comportamento reprodutível dos medicamentos e sua segurança. Por outro lado, a engenharia de cristais moleculares, fundamentada na síntese supramolecular racional de novas formas cristalinas, é uma atraente alternativa para melhoramento de perfi s farmacêuticos sem a necessidade de quebrar ou formar ligações covalentes. O presente trabalho tem como fi nalidade apresentar os principais aspectos relacionados ao polimorfi smo, às estratégias de engenharia de cristais moleculares e às técnicas de caracterização e controle de qualidade de polimorfos de fármacos.
Referências
1. Vippagunta, S. R.; Brittain, H. G.; Grant, D. J. W. Crystalline solids. Advanced Drug Delivery Reviews, v. 48, p. 3-26, 2001.
2. Desiraju, G. R. Polymorphism: the same and not quite the same. Crystal Growth & Design, v. 8, p. 3-5, 2008.
3. Bilton, C.; Howard, J. A. K.; Madhavi, N. N. L.; Nangia, A.; Desiraju, G. R.; Allen, F. H.; Wilson, C. C. When is a polymorph not a polymorph? Helical trimeric O-H center dot center dot center dot O synthons in trans-1,4-diethynylcyclohexane-1,4-diol. Chemical Communications, n. 17, p. 1675-1676, 1999.
4. Lu, J.; Rohani, S. Polymorphism and crystallization of active pharmaceutical ingredients (APIs). Current Medicinal Chemistry, v. 16, p. 884-905, 2009.
5. Hilfi ker, P. Polymorphism in the pharmaceutical industry. Weinheim, Germany: Wiley-VHC, 2006. 433 p.
6. Katrincic, L. M.; Sun Y. T.; Carlton, R. A.; Diederich, A. M.; Mueller, R. L.; VOGT, F. G. Characterization, selection, and development of an orally dosed drug polymorph from an enantiotropically related system. International Journal of Pharmaceutics, v. 366, p. 1-13, 2009.
7. Brittain, H. G. Effects of mechanical processing on phase composition. Journal of Pharmaceutical Sciences, v. 91, p. 1573-1580, 2002.
8. Brittain, H. G. Polymorphism in pharmaceutical solids. New York: Marcel Dekker, 1999. 448 p.
9. Babu, N. J.; Cherukuvada, S.; Thakuria, R.; Nangia, A. Conformational and synthon solymorphism in furosemide (Lasix). Crystal Growth & Design, v. 10, p. 1979-1989, 2010.
10. Kachrimanis, K.; Fucke, K.; Noisternig, M.; Siebenhaar, B.; Griesser, U. J. Effects of moisture and residual solvent on the phase stability of orthorhombic paracetamol. Pharmaceutical Research, v. 25, p. 1440-1449, 2008.
11. Heng, J. Y. Y.; Williams, D. R. Wettability of paracetamol polymorphic forms I and II. Langmuir, v. 22, p. 6905-6909, 2006.
12. Burley, J. C.; Duer, M. J.; Stein, R. S.; Vrcelj, R. M. Enforcing ostwald’s rule of stages: isolation of paracetamol forms III and II. European Journal of Pharmaceutical Sciences, v. 31, p. 271-276, 2007.
13. Zerkowski, J. A.; Macdonald, J. C.; Whitesides, G. M. Polymorphic packing arrangements in a class of engineered organic crystals. Chemistry of Materials, v. 9, p. 1933-1941, 1997.
14. Akutagawa, T.; Koshinaka, H.; Ye, Q.; Noro, S.; Kawamata, J.; Yamaki, H.; Nakamura, T. Conformational polymorph of o-aminoanilinium(dibenzo[18]crown-6) supramolecules in [Ni(dmit)2]- salts. Chemistry-An Asian Journal, v. 5, p. 520-529, 2010.
15. Bhatt, P. M.; Azim, Y.; Thakur, T. S.; Desiraju, G. R. Co-crystals of the anti-HIV drugs lamivudine and zidovudine. Crystal Growth & Design, v. 9, p. 951-957, 2009.
16. Maria, T. M. R.; Castro, R. A. E.; Bebiano, S. S.; Silva, M. R.; Beja, A. M.; Canotilho, J.; Eusebio, M. E. S. Polymorphism of trans-1,4-cyclohexanediol: conformational isomorphism. Crystal Growth & Design, v. 10, p. 1194-1200, 2010.
17. Dey, S. K.; Das, G. Conformational polymorphism of a simple tripodal podand bearing nitro functionality. Crystal Growth & Design, v. 10, p. 754-760, 2010.
18. Sokolov, A. N.; Sumrak, J. C.; Macgillivray, L. R. Conformational polymorphism facilitates assignment of trans and cis-conformers of an alpha-substituted oligothiophene via IR spectroscopy. Chemical Communications, n. 46, p. 82-84, 2010.
19. Uzarevic, K.; Rubcic, M.; Dilovic, I.; Kokan, Z.; Calogovic, D. M.; Cindric, M. Concomitant conformational polymorphism: mechanochemical reactivity and phase relationships in the (methanol)cis-dioxo(N-salicylidene-2-amino-3-hydroxypyridine) molybdenum(VI) trimorph. Crystal Growth & Design, v. 9, p. 5327-5333, 2009.
20. Stahly, G. P. Diversity in single- and multiple-component crystals: the search for and prevalence of polymorphs and cocrystals. Crystal Growth & Design, v. 7, p. 1007-1026, 2007.
21. Monissette, S. L.; Almarsson, O.; Peterson, M. L.; Remenar, J. F.; Read, M. J.; Lemmo, A. V.; Ellis, S.; Cima, M. J.; Gardner, C. R. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Advanced Drug Delivery Reviews, v. 56, p. 275-300, 2004.
22. Braga, D.; Grepioni, F.; Maini, L.; Polito, M. Crystal Polymorphism and Multiple Crystal Forms. Molecular Networks, v. 132, p. 25-50, 2009.
23. Vishweshwar, P.; Mcmahon, J. A.; Peterson, M. L.; Hickey, M. B.; Shattock, T. R.; Zaworotko, M. J. Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients. Chemical Communications, n. 36, p. 4601-4603, 2005.
24. Aakeroy, C. B.; Fasulo, M. E.; Desper, J. Cocrystal or salt: does it really matter? Molecular Pharmaceutics, v. 4, p. 317-322, 2007.
25. Brittain, H. G. Polymorphism and solvatomorphism 2007. Journal of Pharmaceutical Sciences, v. 98, p. 1617-1642, 2009.
26. Vishweshwar, P.; Mcmahon, J. A.; Bis, J. A.; Zaworotko, M. J. Pharmaceutical co-crystal. Journal of Pharmaceutical Sciences, v. 95, p. 499-516, 2006.
27. Childs, S. L.; Stahly, G. P.; Park, A. The salt-cocrystal continuum: the infl uence of crystal structure on ionization state. Molecular Pharmaceutics, v. 4, p. 323-338, 2007.
28. Moulton, B.; Zaworotko, M. J. From molecules to crystal engineering: supramolecular isomerism and polymorphism in network solids. Chemical Reviews, v. 101, p. 1629-1658, 2001.
29. Berstein, J. Polymorphism in molecular crystals. New York: Oxford University Press, 2002. 410 p.
30. Desiraju, G. R. Crystal engineering: solid state supramolecular synthesis. Current Opinion in Solid State & Materials Science, v. 2, p. 451-454, 1997.
31. Elder, D. P.; Delaney, E.; Teasdale, A.; Eyley, S.; Reif, V. D.; Jacq, K.; Facchine, K. L.; Oestrich, R. S.; Sandra, P.; David, F. The utility of sulfonate salts in drug development. Journal of Pharmaceutical Sciences, v. 99, p. 2948-2961, 2010.
32. Cheney, M. L.; Mcmanus, G. J.; Perman, J. A.; Wang, Z. Q.; Zaworotko, M. J. The role of cocrystals in solid-state synthesis: cocrystal-controlled solid-state synthesis of imides. Crystal Growth & Design, v. 7, p. 616-617, 2007.
33. Almarsson, O.; Zaworotko, M. J. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical cocrystals represent a new path to improved medicines? Chemical Communications, n. 17, p. 1889-1896, 2004.
34. Higashi, K.; Ideura, S.; Waraya, H.; Limwikrant, W.; Moribe, K.; Yamamoto, K. Simultaneous dissolution of naproxen and fl urbiprofen from a novel ternary gamma-cyclodextrin complex. Chemical & Pharmaceutical Bulletin, v. 58, p. 769-772, 2010.
35. Dey, A.; Kirchner, M. T.; Vangala, V. R.; Desiraju, G. R.; Mondal, R.; Howard, J. A. K. Crystal structure prediction of aminols: advantages of a supramolecular synthon approach with experimental structures. Journal of the American Chemical Society, v. 127, p. 10545-10559, 2005.
36. Thalladi, V. R.; Weiss, H. C.; Blaser, D.; Boese, R.; Nangia, A.; Desiraju, G. R. C-H center dot center dot center dot Finteractions in the crystal structures of some fl uorobenzenes. Journal of the American Chemical Society, v. 120, p. 8702-8710, 1998.
37. Desiraju, G. R.; Kishan, K. V. R. Crystal-chemistry of some (alkoxyphenyl)propiolic acids - the role of oxygen and hydrogenatoms in determining stack structures of planar aromaticcompounds. Journal of the American Chemical Society, v. 111, p. 4838-4843, 1989.
38. Vangala, V. R.; Bhogala, B. R.; Dey, A.; Desiraju, G. R.; Broder, C. K.; Smith, P. S.; Mondal, R.; Howard, J. A. K.; Wilson, C. C. Correspondence between molecular functionality and crystal structures. Supramolecular chemistry of a family of homologated aminophenols. Journal of the American Chemical Society, v. 125, p. 14495-14509, 2003.
39. Khan, M.; Enkelmann, V.; Brunklaus, G. Crystal engineering of pharmaceutical co-crystals: application of methyl paraben as molecular hook. Journal of the American Chemical Society, v. 132, p. 5254-5263, 2010.
40. Ranjbar, P. R.; Vafakish, B.; Abbasi, A.; Fischer, A. Host-guest interaction in propeller-shaped molecules. Part one: single crystal X-ray analysis of benzylidene-1,1’-bis-2-naphthol solvent cocrystals. Zeitschrift fur Kristallographie, v. 224, p. 499-505, 2009.
41. Martins, F. T.; Paparidis, N.; Doriguetto, A. C.; Ellena, J. Crystal engineering of an anti-HIV drug based on the recognition of assembling molecular frameworks. Crystal Growth and Design, v. 9, p. 5283–5292, 2009.
42. Banerjee, R.; Bhatt, P. M.; Ravindra, N. V.; Desiraju, G. R. Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities. Crystal Growth & Design, v. 5, p. 2299-2309, 2005.
43. Silva, L. A.; Martins, C. R.; Andrade, J. B. Why are all nitrates soluble? Quimica Nova, v. 27, p. 1016-1020, 2004.
44. Khurshid, S.; Haire, L. F.; Chayen, N. E. Automated seeding for the optimization of crystal quality. Journal of Applied Crystallography, v. 43, p. 752-756, 2010.
45. Khan, A. N.; Hong, P. D.; Chuang, W. T.; Shih, K. S. Crystallization kinetics and structure of poly(trimethylene
terepthalate)/monolayer nano-mica nanocomposites. Materials Chemistry and Physics, v. 119, p. 93-99, 2010.
46. Li, H. T.; Kiang, Y. H.; Jona, J. Multiple approaches to pharmaceutical polymorphism investigation - A case study. European Journal of Pharmaceutical Sciences, v. 38, p. 426-432, 2009.
47. Altonen, J.; Alleso, M.; Mirza, S.; Koradia, V.; Gordon, K. C.; Rantanen, J. Solid form screening - A review. European Journal of Pharmaceutics and Biopharmaceutics, v. 71, p. 23-37, 2009.
48. Fabbiani, F. P. A.; Allan, D. R.; David, W. I. F.; Davidson, A. J.; Lennie, A. R.; Parsons, S.; Pulham, C. R.; Warren, J. E. High-pressure studies of pharmaceuticals: an exploration of the behavior of piracetam. Crystal Growth & Design, v. 7, p. 1115-1124, 2007.
49. França, F. F. A. C. Andrejus korolkovas: Dicionário Terapêutico Guanabara. 10. ed. Rio de Janeiro, Guanabara Koogan, 2003.
50. Tracy, J. W.; Webster, L.T. Fármacos Usados No Tratamento Das Helmintíases In: Gilman, A. G.; Hardman, J. G.; Molinoff, P. B. As Bases Farmacológicas da Terapêutica. 9 ed. Rio de janeiro, McGraw - Hill Interamericana Editores, 1996. pp 741-753.
51. Swanepoel, E.; Liebenberg, W.; Devarakonda, B.; De Villiers, M. M. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences. Pharmazie, v. 58, p. 117-121, 2003.
52. Swanepoel, E.; Liebenberg, W.; De Villiers M. M. Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs. European Journal of Pharmaceutics and Biopharmaceutics, v. 55, p. 345-349, 2003.
53. Martins, F. T., Neves, P. P., Ellena, J., Camí, G. E., Brusau, E. V., Narda, G. E. Intermolecular contacts infl uencing the conformational and geometric features of the pharmaceutically preferred mebendazole polymorph C. Journal of Pharmaceutical Sciences, v.98, p.2336 - 2344, 2009.
54. Kountourellis, J. E.; Markopoulou, C. K.; Underwood, F. A.; Chapman, B.; Characterization of 12 diuretics. Journal of Chemical and Engineering Data, v. 37, p. 187-191, 1992.
55. Martins, F. T., Bocelli, M. D., Bonfi lio, R., De Araújo, M. B., De Lima, P. V., Neves, P. P., Veloso, M. P., Ellena, J., Doriguetto, A. C. Conformational Polymorphism in Racemic Crystals of the Diuretic Drug Chlortalidone. Crystal Growth & Design, v.9, p.3235 - 3244, 2009.
56. Chiou, W. L. The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarifi cation and recommendation of terminology. Journal of Pharmacokinetics and Pharmacodynamics, v. 28, p. 3-6, 2001.
57. Swarbrick, J. Current concepts in the biopharmaceutical sciences: dosage form design and bioavailability. Philadelphia: Lea & Febiger, 1973. 230 p.
58. Chiou, W. L.; Chung, S. M.; Wu, T. C. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharmaceutical Research, v. 17, p. 205-208, 2000.
59. Chiou, W. L.; Buehler, P. W. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharmaceutical Research, v. 19, p. 868-874, 2002.
60. Khan, M. Z. I. Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities. International Journal of Pharmaceutics, v. 140, p. 131-143, 1996.
61. Hersey, J. A.; Marty, J. J. Drug dissolution - Critical review. Manufacturing Chemist and Aerosol News, v. 46, p. 43-53, 1975.
62. Manadas, R.; Pina, M. E.; Veiga, F. A dissolução in vitro na previsão da absorção oral de fármacos em formas farmacêuticas de liberação modifi cada. Brazilian Journal of Pharmaceutical Sciences, v. 38, p. 375-400, 2002.
63. Huang, L. F.; Tong, W. Q. Impact of solid state properties on developability assessment of drug candidates. Advanced Drug Delivery Reviews, v. 56, p. 321-334, 2004.
64. Horter, D.; Dressman, J. B. Infl uence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Advanced Drug Delivery Reviews, v. 46, p. 75-87, 2001.
65. Kreyes, A.; Ellinger, S.; Landfester, K.; Defaux, M.; Ivanov, D. A.; Elschner, A.; Friedrichsen, T. M.; Ziener, U. Fine tuning of solid-state properties of septithiophenes by tailoring the substituents. Chemistry of Materials, v. 22, p. 2079-2092, 2010.
66. Bhatt, P. M.; Ravindra, N. V.; Banerjee, R.; Desiraju, G. R. Saccharin as a salt former: enhanced solubilities of saccharinates of active pharmaceutical ingredients. Chemical Communications, n. 8, p. 1073-1075, 2005.
67. Parshad, H.; Frydenvang, K.; Liljefors, T.; Larsen, C. S. Correlation of aqueous solubility of salts of benzylamine with experimentally and theoretically derived parameters. A multivariate data analysis approach. International Journal of Pharmaceutics, v. 237, p. 193-207, 2002.
68. Surov, A. O.; Szterner, P.; Zielenkiewicz, W.; Perlovich, G. L. Thermodynamic and structural study of tolfenamic acid polymorphs. Journal of Pharmaceutical and Biomedical Analysis, v. 50, p. 831-840, 2009.
69. Serajuddin, A. T. M. Salt formation to improve drug solubility. Advanced Drug Delivery Reviews, v. 59, p. 603-616, 2007.
70. Paulekuhn, G. S.; Dressman, J. B.; Saal, C. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book Database. Journal of Medicinal Chemistry, v. 50, p. 6665-6672, 2007.
71. Stahl P. H.; Wermuth, C. G. Handbook of pharmaceutical salts: properties, selection, and use. Weinheim, Germany: Wiley-VHC, 2002. 374 p.
72. Jones, H. P.; Davey, R. J.; Cox, B. G. Crystallization of a salt of a weak organic acid and base: solubility relations, supersaturation control and polymorphic behavior. Journal of Physical Chemistry B, v. 109, p. 5273-5278, 2005.
73. Daiichi Sankyo K.K. Y Nakamura; C. Sato; T. Miyamoto; H. Kajino. Pharmaceutical composition for treating diabetes, hyperlipidemia, polycystic ovarian syndrome or atherosclerosis, has crystal of 5-4-6-methoxy-1-methyl-1H-benzimidazole2-yl-methoxy-benzyl thiazolidine-2,4-dione hydrochloride. JP2008044932-A, 28 Feb. 2008.
74. Synthon BV. R. J. H. Westheim. New crystalline erlotinib hydrochloride hydrate is epidermal growth factor receptor tyrosine kinase inhibitor useful for preparing anhydrous erlotinib hydrochloride and treating proliferative disorders and cancer e.g. ovarian cancer. WO2008049645-A2, 02 May 2008.
75. Dipharma Spa. G. Castaldi; G. Barreca; P. Allegrini; G. Ventimiglia; G. Balleca; J. Ventimilia. New monohydrate crystalline form of fexofenadine hydrochloride useful in therapy and as antihistaminic, antiallergic and bronchodilator medicaments. US2005282860-A1, 22 Dec. 2005.
76. Kissei Pharm Co Ltd. H. Isawa; M. Toda. Crystal of specifi cdimethyl phenoxy ethyl acetate hydrochloride hydrate derivative used in pharmaceutical composition for preventing and treating diseases such as urinary incontinence, neurogenic bladder dysfunction and nocturia. WO2006118087-A1, 09 Nov. 2006.
77. Cipla Ltd. D. R. Rao; R. Kankan. New crystalline form of sibutramine (N-(1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl)-N,N-dimethyl-amine) free base is a neuronal monoamine reuptake inhibitor useful to treat/prevent/ameliorate/eliminate e.g. depression. KR2006034636-A, 18 Nov. 2004.
78. Wyeth Corp. J. Schmid; J. J. Bicksler. New hydrochloride salt of quinoline and its crystalline monohydrochloride salt useful for treating e.g. dementia, Alzheimer’s disease, schizophrenia and depression. WO2007146115-A2, 21 Dec. 2007.
79. Li, S. F.; Doyle, P.; Metz, S.; Royce, A. E.; Serajuddin, A. T. M. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug. Journal of Pharmaceutical Sciences, v. 94, p. 2224-2231, 2005.
80. Schering Corp. M. Hu; S. Paliwal; N. Shih; F. Guenter; I. Mergelsberg. New crystalline esylate, mesylate, maleate and oxalate salt forms of (5S,8S)-8-(((1R)-1-(3,5-bis-(trifl uoromethyl)phenyl)-ethoxy)-methyl)-8-henyl-1,7-diazaspiro(4.5)decan-2-one, useful in pharmaceutical composition for treating nausea. WO2007114922-A2, 11 Oct. 2007.
81. Reddy’s Lab Ltd. S. Eswaraiah; G. M. Reddy; J. M. Reddy; K. V. Rambabu; B. V. Bhaskar. New crystalline forms I and II of amlodipine maleate useful as anti-ischemic and anti-hypertensive agents. US2007004783-A1, 04 Jan. 2007.
82. Fini, A.; Fazio, G.; Rodriguez, M. G.; Cavallari, C.; Passerini, N.; Rodríguez, L. Formation of ion-pairs in aqueous solutions of diclofenac salts. International of Journal Pharmaceutics, v. 187, p. 163-173, 1999.
83. O’Connor, K. M.; Corrigan, O. I. Preparation and characterization of a range of diclofenac salts. International of Journal Pharmaceutics, v. 226, p. 163-179, 2001.
84. O’Connor, K. M.; Corrigan, O. I. Comparison of the physicochemical properties of the N-(2-hydroxyethyl) pyrrolidine, diethylamine and sodium salt forms of diclofenac. International of Journal Pharmaceutics, v. 222, p. 281-293, 2001.
85. Tantishaiyakul, V. Prediction of aqueous solubility of organic salts of diclofenac using PLS and molecular modeling. International of Journal Pharmaceutics, v. 275, p. 133-139, 2004.
86. Raw, A. S.; Furness, M. S.; Gill, D. S.; Adams, R. C.; Holcombe, F. O.; Yu, L. X. Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAs). Advanced Drug Delivery Reviews, v. 56, p. 397-414, 2004.
87. Carini, J. P.; Pavei, C.; Silva, A. P. C.; Machado, G.; Mexias, A. S.; Pereira, V. P.; Fialho, S. L.; Mayorga, P. Solid state evaluation of some thalidomide raw materials. International Journal of Pharmaceutics, v. 372, p. 17-23, 2009.
88. Romero, A. J.; Savastano, L.; Rhodes, C. T. Monitoring crystal modifi cations in systems containing ibuprofen. International Journal of Pharmaceutics, v. 99, p. 125-134, 1993.
89. Silva, C. C. P.; Martins, F. T.; Honorato, S. B.; Boechat, N.; Ayala, A. P.; Ellena, J. Triple structural transition below room temperature in the antifi larial drug diethylcarbamazine citrate. Crystal Growth & Design, v. 10, p. 3094-3101, 2010.
90. Roy, S.; Aitipamula, S.; Nangia, A. Thermochemical analysis of venlafaxine hydrochloride polymorphs 1-5. Crystal Growth & Design, v. 5, p. 2268-2276, 2005.
91. Zencirci, N.; Gelbrich, T.; Apperley, D. C.; Harris, R. K.; Kahlenberg, V.; Griesser, U. J. Structural features, phase relationships and transformation behavior of the polymorphs I-VI of phenobarbital. Crystal Growth & Design, v. 10, p. 302-313, 2010.
92. Skorda, D.; Kontoyannis, C. G. Identifi cation and quantitative determination of atorvastatin calcium polymorph in tablets using FT-Raman spectroscopy. Talanta, v. 74, p. 1066-1070, 2008.
93. Virtanen, T.; Maunu, S. L. Quantifi cation of a polymorphic mixture of an active pharmaceutical ingredient with solid state C-13 CPMAS NMR spectroscopy. International Journal of Pharmaceutics, v. 394, p. 18-25, 2010.
94. Brittain, H. G. X-ray diffraction II: using single-crystal X-ray diffraction to study polymorphism and solvatomorphism. Spectroscopy, v. 15, p. 34-39, 2000.
95. Ferreira, F. F.; Antoni, S. G.; Rosa, P. C. P.; Santos, C. D. P. Crystal structure determination of mebendazole form a using high-resolution synchrotron X-ray powder diffraction data. Journal of Pharmaceutical Sciences, v. 99, p. 1734-1744, 2010.
96. Caira, M. R.; Bettinetti, G.; Sorrenti, M.; Catenacci, L. Relationships between structural and thermal properties of anhydrous and solvated crystalline forms of brodimoprim. Journal of Pharmaceutical Sciences, v. 96, p. 996-1007, 2007.
97. Jankovic, B.; Mentus, S. Thermal stability and nonisothermal kinetics of Folnak (R) degradation process. Drug Development and Industrial Pharmacy, v. 36, p. 980-992, 2010.
98. Giacovazzo, C. Fundamentals of crystallography. New York: Oxford University Press, 1992. 674 p.
99. Stephenson, G. A. Structure determination from conventional powder diffraction data: application to hydrates, hydrochloride salts, and metastable polymorphs. Journal of Pharmaceutical Sciences, v. 89, p. 958-966, 2000.
100. Yu, L. X.; Furness, M. S.; Raw, A.; Outlaw, K. P. W.; Nashed, N. E.; Ramos, E.; Miller, S. P. F.; Adams, R. C.; Fang, F.; Patel, R. M.; Holcombe, F. O.; Chiu, Y. Y.; Hussain, A. S. Scientifi c considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharmaceutical Research, v. 20, p. 531-536, 2003.
101. The United States Pharmacopeia XXXI and National Formulary XXVI; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2008.
2. Desiraju, G. R. Polymorphism: the same and not quite the same. Crystal Growth & Design, v. 8, p. 3-5, 2008.
3. Bilton, C.; Howard, J. A. K.; Madhavi, N. N. L.; Nangia, A.; Desiraju, G. R.; Allen, F. H.; Wilson, C. C. When is a polymorph not a polymorph? Helical trimeric O-H center dot center dot center dot O synthons in trans-1,4-diethynylcyclohexane-1,4-diol. Chemical Communications, n. 17, p. 1675-1676, 1999.
4. Lu, J.; Rohani, S. Polymorphism and crystallization of active pharmaceutical ingredients (APIs). Current Medicinal Chemistry, v. 16, p. 884-905, 2009.
5. Hilfi ker, P. Polymorphism in the pharmaceutical industry. Weinheim, Germany: Wiley-VHC, 2006. 433 p.
6. Katrincic, L. M.; Sun Y. T.; Carlton, R. A.; Diederich, A. M.; Mueller, R. L.; VOGT, F. G. Characterization, selection, and development of an orally dosed drug polymorph from an enantiotropically related system. International Journal of Pharmaceutics, v. 366, p. 1-13, 2009.
7. Brittain, H. G. Effects of mechanical processing on phase composition. Journal of Pharmaceutical Sciences, v. 91, p. 1573-1580, 2002.
8. Brittain, H. G. Polymorphism in pharmaceutical solids. New York: Marcel Dekker, 1999. 448 p.
9. Babu, N. J.; Cherukuvada, S.; Thakuria, R.; Nangia, A. Conformational and synthon solymorphism in furosemide (Lasix). Crystal Growth & Design, v. 10, p. 1979-1989, 2010.
10. Kachrimanis, K.; Fucke, K.; Noisternig, M.; Siebenhaar, B.; Griesser, U. J. Effects of moisture and residual solvent on the phase stability of orthorhombic paracetamol. Pharmaceutical Research, v. 25, p. 1440-1449, 2008.
11. Heng, J. Y. Y.; Williams, D. R. Wettability of paracetamol polymorphic forms I and II. Langmuir, v. 22, p. 6905-6909, 2006.
12. Burley, J. C.; Duer, M. J.; Stein, R. S.; Vrcelj, R. M. Enforcing ostwald’s rule of stages: isolation of paracetamol forms III and II. European Journal of Pharmaceutical Sciences, v. 31, p. 271-276, 2007.
13. Zerkowski, J. A.; Macdonald, J. C.; Whitesides, G. M. Polymorphic packing arrangements in a class of engineered organic crystals. Chemistry of Materials, v. 9, p. 1933-1941, 1997.
14. Akutagawa, T.; Koshinaka, H.; Ye, Q.; Noro, S.; Kawamata, J.; Yamaki, H.; Nakamura, T. Conformational polymorph of o-aminoanilinium(dibenzo[18]crown-6) supramolecules in [Ni(dmit)2]- salts. Chemistry-An Asian Journal, v. 5, p. 520-529, 2010.
15. Bhatt, P. M.; Azim, Y.; Thakur, T. S.; Desiraju, G. R. Co-crystals of the anti-HIV drugs lamivudine and zidovudine. Crystal Growth & Design, v. 9, p. 951-957, 2009.
16. Maria, T. M. R.; Castro, R. A. E.; Bebiano, S. S.; Silva, M. R.; Beja, A. M.; Canotilho, J.; Eusebio, M. E. S. Polymorphism of trans-1,4-cyclohexanediol: conformational isomorphism. Crystal Growth & Design, v. 10, p. 1194-1200, 2010.
17. Dey, S. K.; Das, G. Conformational polymorphism of a simple tripodal podand bearing nitro functionality. Crystal Growth & Design, v. 10, p. 754-760, 2010.
18. Sokolov, A. N.; Sumrak, J. C.; Macgillivray, L. R. Conformational polymorphism facilitates assignment of trans and cis-conformers of an alpha-substituted oligothiophene via IR spectroscopy. Chemical Communications, n. 46, p. 82-84, 2010.
19. Uzarevic, K.; Rubcic, M.; Dilovic, I.; Kokan, Z.; Calogovic, D. M.; Cindric, M. Concomitant conformational polymorphism: mechanochemical reactivity and phase relationships in the (methanol)cis-dioxo(N-salicylidene-2-amino-3-hydroxypyridine) molybdenum(VI) trimorph. Crystal Growth & Design, v. 9, p. 5327-5333, 2009.
20. Stahly, G. P. Diversity in single- and multiple-component crystals: the search for and prevalence of polymorphs and cocrystals. Crystal Growth & Design, v. 7, p. 1007-1026, 2007.
21. Monissette, S. L.; Almarsson, O.; Peterson, M. L.; Remenar, J. F.; Read, M. J.; Lemmo, A. V.; Ellis, S.; Cima, M. J.; Gardner, C. R. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Advanced Drug Delivery Reviews, v. 56, p. 275-300, 2004.
22. Braga, D.; Grepioni, F.; Maini, L.; Polito, M. Crystal Polymorphism and Multiple Crystal Forms. Molecular Networks, v. 132, p. 25-50, 2009.
23. Vishweshwar, P.; Mcmahon, J. A.; Peterson, M. L.; Hickey, M. B.; Shattock, T. R.; Zaworotko, M. J. Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients. Chemical Communications, n. 36, p. 4601-4603, 2005.
24. Aakeroy, C. B.; Fasulo, M. E.; Desper, J. Cocrystal or salt: does it really matter? Molecular Pharmaceutics, v. 4, p. 317-322, 2007.
25. Brittain, H. G. Polymorphism and solvatomorphism 2007. Journal of Pharmaceutical Sciences, v. 98, p. 1617-1642, 2009.
26. Vishweshwar, P.; Mcmahon, J. A.; Bis, J. A.; Zaworotko, M. J. Pharmaceutical co-crystal. Journal of Pharmaceutical Sciences, v. 95, p. 499-516, 2006.
27. Childs, S. L.; Stahly, G. P.; Park, A. The salt-cocrystal continuum: the infl uence of crystal structure on ionization state. Molecular Pharmaceutics, v. 4, p. 323-338, 2007.
28. Moulton, B.; Zaworotko, M. J. From molecules to crystal engineering: supramolecular isomerism and polymorphism in network solids. Chemical Reviews, v. 101, p. 1629-1658, 2001.
29. Berstein, J. Polymorphism in molecular crystals. New York: Oxford University Press, 2002. 410 p.
30. Desiraju, G. R. Crystal engineering: solid state supramolecular synthesis. Current Opinion in Solid State & Materials Science, v. 2, p. 451-454, 1997.
31. Elder, D. P.; Delaney, E.; Teasdale, A.; Eyley, S.; Reif, V. D.; Jacq, K.; Facchine, K. L.; Oestrich, R. S.; Sandra, P.; David, F. The utility of sulfonate salts in drug development. Journal of Pharmaceutical Sciences, v. 99, p. 2948-2961, 2010.
32. Cheney, M. L.; Mcmanus, G. J.; Perman, J. A.; Wang, Z. Q.; Zaworotko, M. J. The role of cocrystals in solid-state synthesis: cocrystal-controlled solid-state synthesis of imides. Crystal Growth & Design, v. 7, p. 616-617, 2007.
33. Almarsson, O.; Zaworotko, M. J. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical cocrystals represent a new path to improved medicines? Chemical Communications, n. 17, p. 1889-1896, 2004.
34. Higashi, K.; Ideura, S.; Waraya, H.; Limwikrant, W.; Moribe, K.; Yamamoto, K. Simultaneous dissolution of naproxen and fl urbiprofen from a novel ternary gamma-cyclodextrin complex. Chemical & Pharmaceutical Bulletin, v. 58, p. 769-772, 2010.
35. Dey, A.; Kirchner, M. T.; Vangala, V. R.; Desiraju, G. R.; Mondal, R.; Howard, J. A. K. Crystal structure prediction of aminols: advantages of a supramolecular synthon approach with experimental structures. Journal of the American Chemical Society, v. 127, p. 10545-10559, 2005.
36. Thalladi, V. R.; Weiss, H. C.; Blaser, D.; Boese, R.; Nangia, A.; Desiraju, G. R. C-H center dot center dot center dot Finteractions in the crystal structures of some fl uorobenzenes. Journal of the American Chemical Society, v. 120, p. 8702-8710, 1998.
37. Desiraju, G. R.; Kishan, K. V. R. Crystal-chemistry of some (alkoxyphenyl)propiolic acids - the role of oxygen and hydrogenatoms in determining stack structures of planar aromaticcompounds. Journal of the American Chemical Society, v. 111, p. 4838-4843, 1989.
38. Vangala, V. R.; Bhogala, B. R.; Dey, A.; Desiraju, G. R.; Broder, C. K.; Smith, P. S.; Mondal, R.; Howard, J. A. K.; Wilson, C. C. Correspondence between molecular functionality and crystal structures. Supramolecular chemistry of a family of homologated aminophenols. Journal of the American Chemical Society, v. 125, p. 14495-14509, 2003.
39. Khan, M.; Enkelmann, V.; Brunklaus, G. Crystal engineering of pharmaceutical co-crystals: application of methyl paraben as molecular hook. Journal of the American Chemical Society, v. 132, p. 5254-5263, 2010.
40. Ranjbar, P. R.; Vafakish, B.; Abbasi, A.; Fischer, A. Host-guest interaction in propeller-shaped molecules. Part one: single crystal X-ray analysis of benzylidene-1,1’-bis-2-naphthol solvent cocrystals. Zeitschrift fur Kristallographie, v. 224, p. 499-505, 2009.
41. Martins, F. T.; Paparidis, N.; Doriguetto, A. C.; Ellena, J. Crystal engineering of an anti-HIV drug based on the recognition of assembling molecular frameworks. Crystal Growth and Design, v. 9, p. 5283–5292, 2009.
42. Banerjee, R.; Bhatt, P. M.; Ravindra, N. V.; Desiraju, G. R. Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities. Crystal Growth & Design, v. 5, p. 2299-2309, 2005.
43. Silva, L. A.; Martins, C. R.; Andrade, J. B. Why are all nitrates soluble? Quimica Nova, v. 27, p. 1016-1020, 2004.
44. Khurshid, S.; Haire, L. F.; Chayen, N. E. Automated seeding for the optimization of crystal quality. Journal of Applied Crystallography, v. 43, p. 752-756, 2010.
45. Khan, A. N.; Hong, P. D.; Chuang, W. T.; Shih, K. S. Crystallization kinetics and structure of poly(trimethylene
terepthalate)/monolayer nano-mica nanocomposites. Materials Chemistry and Physics, v. 119, p. 93-99, 2010.
46. Li, H. T.; Kiang, Y. H.; Jona, J. Multiple approaches to pharmaceutical polymorphism investigation - A case study. European Journal of Pharmaceutical Sciences, v. 38, p. 426-432, 2009.
47. Altonen, J.; Alleso, M.; Mirza, S.; Koradia, V.; Gordon, K. C.; Rantanen, J. Solid form screening - A review. European Journal of Pharmaceutics and Biopharmaceutics, v. 71, p. 23-37, 2009.
48. Fabbiani, F. P. A.; Allan, D. R.; David, W. I. F.; Davidson, A. J.; Lennie, A. R.; Parsons, S.; Pulham, C. R.; Warren, J. E. High-pressure studies of pharmaceuticals: an exploration of the behavior of piracetam. Crystal Growth & Design, v. 7, p. 1115-1124, 2007.
49. França, F. F. A. C. Andrejus korolkovas: Dicionário Terapêutico Guanabara. 10. ed. Rio de Janeiro, Guanabara Koogan, 2003.
50. Tracy, J. W.; Webster, L.T. Fármacos Usados No Tratamento Das Helmintíases In: Gilman, A. G.; Hardman, J. G.; Molinoff, P. B. As Bases Farmacológicas da Terapêutica. 9 ed. Rio de janeiro, McGraw - Hill Interamericana Editores, 1996. pp 741-753.
51. Swanepoel, E.; Liebenberg, W.; Devarakonda, B.; De Villiers, M. M. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences. Pharmazie, v. 58, p. 117-121, 2003.
52. Swanepoel, E.; Liebenberg, W.; De Villiers M. M. Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs. European Journal of Pharmaceutics and Biopharmaceutics, v. 55, p. 345-349, 2003.
53. Martins, F. T., Neves, P. P., Ellena, J., Camí, G. E., Brusau, E. V., Narda, G. E. Intermolecular contacts infl uencing the conformational and geometric features of the pharmaceutically preferred mebendazole polymorph C. Journal of Pharmaceutical Sciences, v.98, p.2336 - 2344, 2009.
54. Kountourellis, J. E.; Markopoulou, C. K.; Underwood, F. A.; Chapman, B.; Characterization of 12 diuretics. Journal of Chemical and Engineering Data, v. 37, p. 187-191, 1992.
55. Martins, F. T., Bocelli, M. D., Bonfi lio, R., De Araújo, M. B., De Lima, P. V., Neves, P. P., Veloso, M. P., Ellena, J., Doriguetto, A. C. Conformational Polymorphism in Racemic Crystals of the Diuretic Drug Chlortalidone. Crystal Growth & Design, v.9, p.3235 - 3244, 2009.
56. Chiou, W. L. The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarifi cation and recommendation of terminology. Journal of Pharmacokinetics and Pharmacodynamics, v. 28, p. 3-6, 2001.
57. Swarbrick, J. Current concepts in the biopharmaceutical sciences: dosage form design and bioavailability. Philadelphia: Lea & Febiger, 1973. 230 p.
58. Chiou, W. L.; Chung, S. M.; Wu, T. C. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharmaceutical Research, v. 17, p. 205-208, 2000.
59. Chiou, W. L.; Buehler, P. W. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharmaceutical Research, v. 19, p. 868-874, 2002.
60. Khan, M. Z. I. Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities. International Journal of Pharmaceutics, v. 140, p. 131-143, 1996.
61. Hersey, J. A.; Marty, J. J. Drug dissolution - Critical review. Manufacturing Chemist and Aerosol News, v. 46, p. 43-53, 1975.
62. Manadas, R.; Pina, M. E.; Veiga, F. A dissolução in vitro na previsão da absorção oral de fármacos em formas farmacêuticas de liberação modifi cada. Brazilian Journal of Pharmaceutical Sciences, v. 38, p. 375-400, 2002.
63. Huang, L. F.; Tong, W. Q. Impact of solid state properties on developability assessment of drug candidates. Advanced Drug Delivery Reviews, v. 56, p. 321-334, 2004.
64. Horter, D.; Dressman, J. B. Infl uence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Advanced Drug Delivery Reviews, v. 46, p. 75-87, 2001.
65. Kreyes, A.; Ellinger, S.; Landfester, K.; Defaux, M.; Ivanov, D. A.; Elschner, A.; Friedrichsen, T. M.; Ziener, U. Fine tuning of solid-state properties of septithiophenes by tailoring the substituents. Chemistry of Materials, v. 22, p. 2079-2092, 2010.
66. Bhatt, P. M.; Ravindra, N. V.; Banerjee, R.; Desiraju, G. R. Saccharin as a salt former: enhanced solubilities of saccharinates of active pharmaceutical ingredients. Chemical Communications, n. 8, p. 1073-1075, 2005.
67. Parshad, H.; Frydenvang, K.; Liljefors, T.; Larsen, C. S. Correlation of aqueous solubility of salts of benzylamine with experimentally and theoretically derived parameters. A multivariate data analysis approach. International Journal of Pharmaceutics, v. 237, p. 193-207, 2002.
68. Surov, A. O.; Szterner, P.; Zielenkiewicz, W.; Perlovich, G. L. Thermodynamic and structural study of tolfenamic acid polymorphs. Journal of Pharmaceutical and Biomedical Analysis, v. 50, p. 831-840, 2009.
69. Serajuddin, A. T. M. Salt formation to improve drug solubility. Advanced Drug Delivery Reviews, v. 59, p. 603-616, 2007.
70. Paulekuhn, G. S.; Dressman, J. B.; Saal, C. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book Database. Journal of Medicinal Chemistry, v. 50, p. 6665-6672, 2007.
71. Stahl P. H.; Wermuth, C. G. Handbook of pharmaceutical salts: properties, selection, and use. Weinheim, Germany: Wiley-VHC, 2002. 374 p.
72. Jones, H. P.; Davey, R. J.; Cox, B. G. Crystallization of a salt of a weak organic acid and base: solubility relations, supersaturation control and polymorphic behavior. Journal of Physical Chemistry B, v. 109, p. 5273-5278, 2005.
73. Daiichi Sankyo K.K. Y Nakamura; C. Sato; T. Miyamoto; H. Kajino. Pharmaceutical composition for treating diabetes, hyperlipidemia, polycystic ovarian syndrome or atherosclerosis, has crystal of 5-4-6-methoxy-1-methyl-1H-benzimidazole2-yl-methoxy-benzyl thiazolidine-2,4-dione hydrochloride. JP2008044932-A, 28 Feb. 2008.
74. Synthon BV. R. J. H. Westheim. New crystalline erlotinib hydrochloride hydrate is epidermal growth factor receptor tyrosine kinase inhibitor useful for preparing anhydrous erlotinib hydrochloride and treating proliferative disorders and cancer e.g. ovarian cancer. WO2008049645-A2, 02 May 2008.
75. Dipharma Spa. G. Castaldi; G. Barreca; P. Allegrini; G. Ventimiglia; G. Balleca; J. Ventimilia. New monohydrate crystalline form of fexofenadine hydrochloride useful in therapy and as antihistaminic, antiallergic and bronchodilator medicaments. US2005282860-A1, 22 Dec. 2005.
76. Kissei Pharm Co Ltd. H. Isawa; M. Toda. Crystal of specifi cdimethyl phenoxy ethyl acetate hydrochloride hydrate derivative used in pharmaceutical composition for preventing and treating diseases such as urinary incontinence, neurogenic bladder dysfunction and nocturia. WO2006118087-A1, 09 Nov. 2006.
77. Cipla Ltd. D. R. Rao; R. Kankan. New crystalline form of sibutramine (N-(1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl)-N,N-dimethyl-amine) free base is a neuronal monoamine reuptake inhibitor useful to treat/prevent/ameliorate/eliminate e.g. depression. KR2006034636-A, 18 Nov. 2004.
78. Wyeth Corp. J. Schmid; J. J. Bicksler. New hydrochloride salt of quinoline and its crystalline monohydrochloride salt useful for treating e.g. dementia, Alzheimer’s disease, schizophrenia and depression. WO2007146115-A2, 21 Dec. 2007.
79. Li, S. F.; Doyle, P.; Metz, S.; Royce, A. E.; Serajuddin, A. T. M. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug. Journal of Pharmaceutical Sciences, v. 94, p. 2224-2231, 2005.
80. Schering Corp. M. Hu; S. Paliwal; N. Shih; F. Guenter; I. Mergelsberg. New crystalline esylate, mesylate, maleate and oxalate salt forms of (5S,8S)-8-(((1R)-1-(3,5-bis-(trifl uoromethyl)phenyl)-ethoxy)-methyl)-8-henyl-1,7-diazaspiro(4.5)decan-2-one, useful in pharmaceutical composition for treating nausea. WO2007114922-A2, 11 Oct. 2007.
81. Reddy’s Lab Ltd. S. Eswaraiah; G. M. Reddy; J. M. Reddy; K. V. Rambabu; B. V. Bhaskar. New crystalline forms I and II of amlodipine maleate useful as anti-ischemic and anti-hypertensive agents. US2007004783-A1, 04 Jan. 2007.
82. Fini, A.; Fazio, G.; Rodriguez, M. G.; Cavallari, C.; Passerini, N.; Rodríguez, L. Formation of ion-pairs in aqueous solutions of diclofenac salts. International of Journal Pharmaceutics, v. 187, p. 163-173, 1999.
83. O’Connor, K. M.; Corrigan, O. I. Preparation and characterization of a range of diclofenac salts. International of Journal Pharmaceutics, v. 226, p. 163-179, 2001.
84. O’Connor, K. M.; Corrigan, O. I. Comparison of the physicochemical properties of the N-(2-hydroxyethyl) pyrrolidine, diethylamine and sodium salt forms of diclofenac. International of Journal Pharmaceutics, v. 222, p. 281-293, 2001.
85. Tantishaiyakul, V. Prediction of aqueous solubility of organic salts of diclofenac using PLS and molecular modeling. International of Journal Pharmaceutics, v. 275, p. 133-139, 2004.
86. Raw, A. S.; Furness, M. S.; Gill, D. S.; Adams, R. C.; Holcombe, F. O.; Yu, L. X. Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAs). Advanced Drug Delivery Reviews, v. 56, p. 397-414, 2004.
87. Carini, J. P.; Pavei, C.; Silva, A. P. C.; Machado, G.; Mexias, A. S.; Pereira, V. P.; Fialho, S. L.; Mayorga, P. Solid state evaluation of some thalidomide raw materials. International Journal of Pharmaceutics, v. 372, p. 17-23, 2009.
88. Romero, A. J.; Savastano, L.; Rhodes, C. T. Monitoring crystal modifi cations in systems containing ibuprofen. International Journal of Pharmaceutics, v. 99, p. 125-134, 1993.
89. Silva, C. C. P.; Martins, F. T.; Honorato, S. B.; Boechat, N.; Ayala, A. P.; Ellena, J. Triple structural transition below room temperature in the antifi larial drug diethylcarbamazine citrate. Crystal Growth & Design, v. 10, p. 3094-3101, 2010.
90. Roy, S.; Aitipamula, S.; Nangia, A. Thermochemical analysis of venlafaxine hydrochloride polymorphs 1-5. Crystal Growth & Design, v. 5, p. 2268-2276, 2005.
91. Zencirci, N.; Gelbrich, T.; Apperley, D. C.; Harris, R. K.; Kahlenberg, V.; Griesser, U. J. Structural features, phase relationships and transformation behavior of the polymorphs I-VI of phenobarbital. Crystal Growth & Design, v. 10, p. 302-313, 2010.
92. Skorda, D.; Kontoyannis, C. G. Identifi cation and quantitative determination of atorvastatin calcium polymorph in tablets using FT-Raman spectroscopy. Talanta, v. 74, p. 1066-1070, 2008.
93. Virtanen, T.; Maunu, S. L. Quantifi cation of a polymorphic mixture of an active pharmaceutical ingredient with solid state C-13 CPMAS NMR spectroscopy. International Journal of Pharmaceutics, v. 394, p. 18-25, 2010.
94. Brittain, H. G. X-ray diffraction II: using single-crystal X-ray diffraction to study polymorphism and solvatomorphism. Spectroscopy, v. 15, p. 34-39, 2000.
95. Ferreira, F. F.; Antoni, S. G.; Rosa, P. C. P.; Santos, C. D. P. Crystal structure determination of mebendazole form a using high-resolution synchrotron X-ray powder diffraction data. Journal of Pharmaceutical Sciences, v. 99, p. 1734-1744, 2010.
96. Caira, M. R.; Bettinetti, G.; Sorrenti, M.; Catenacci, L. Relationships between structural and thermal properties of anhydrous and solvated crystalline forms of brodimoprim. Journal of Pharmaceutical Sciences, v. 96, p. 996-1007, 2007.
97. Jankovic, B.; Mentus, S. Thermal stability and nonisothermal kinetics of Folnak (R) degradation process. Drug Development and Industrial Pharmacy, v. 36, p. 980-992, 2010.
98. Giacovazzo, C. Fundamentals of crystallography. New York: Oxford University Press, 1992. 674 p.
99. Stephenson, G. A. Structure determination from conventional powder diffraction data: application to hydrates, hydrochloride salts, and metastable polymorphs. Journal of Pharmaceutical Sciences, v. 89, p. 958-966, 2000.
100. Yu, L. X.; Furness, M. S.; Raw, A.; Outlaw, K. P. W.; Nashed, N. E.; Ramos, E.; Miller, S. P. F.; Adams, R. C.; Fang, F.; Patel, R. M.; Holcombe, F. O.; Chiu, Y. Y.; Hussain, A. S. Scientifi c considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharmaceutical Research, v. 20, p. 531-536, 2003.
101. The United States Pharmacopeia XXXI and National Formulary XXVI; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2008.
Publicado
2010-07-01
Como Citar
Martins, F. T. (2010). Aplicações Tecnológicas do Polimorfismo Farmacêutico. Revista Processos Químicos, 4(8), 9-21. https://doi.org/10.19142/rpq.v4i8.114
Seção
Artigos Convidados
Copyright (c) Revista Processos Químicos
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
